www.mayflowerbio.com
Sales & Support: 314-485-5210

*

Duvelisib

Supplier:
Catalogue number:
10-4788-01
Size:
5 mg
Product is available in:
  • USA
  • Canada
$65.00 Shipping is calculated in checkout

Kinase inhibitor: PI3K inhibitor

  • Datasheet:   view or download
  • Applications:Cancer drug expected to limit 'cytokine storm' induced by SARS-CoV-2
Product Type:

Biochemicals & reagents

CAS Number:

1201438-56-3

Alternative Names:

IPI-145

Range:

1) Winkler et al. (2013), PI3K-δ and PI3K-γ Inhibition by IPI-145 Abrogates Immune Response and Suppresses Activity in Autoimmune and Inflammatory Disease Models; Chem. Biol. 20 1309 2) Dong et al. (2014), IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells; Blood 124 3583 3) Flinn et al. (2018), Duvelisib, a novel dual inhibitor of PI3K-δ/γ, is clinically active in advances hematologic malignancies; Blood 131 877 4) Faia et al. (2018), The phosphoinositide-3 kinase (PI3K)-δ,γ inhibitor, duvelisib, shows preclinical synergy with multiple targeted therapies in hematologic malignancies; PLoS One 13 e0200725 5) Davis et al. (2017), Anti-PD-L1 Efficacy Can Be Enhanced by Inhibition of Myeloid-Derived Suppressor Cells with a Selective Inhibitor of PI3Kδ/γ; Cancer Res. 77 2607

Limit of Detection:

416.87

Storage Temperature:

-20°C (des.)

Additional Information:

Duvelisib (1201438-56-3) is a potent and selective (IC50’s: PI3Kα = 1602nM, PI3Kβ = 85nM, PI3Kδ= 2.5nM, PI3Kγ = 27nM) dual PI3Kδ/γ inhibitor.1 It inhibits B and T cell proliferation, blocks neutrophil migration, and inhibits basophil activation. Duvelisib antagonizes B-cell receptor crosslinking activated pro-survival signals in primary chronic lymphocytic leukemia cells.2 Duvelisib also shows preclinical/clinical activity against other hematologic malignancies such as Non-Hodgkins lymphoma, T-cell lymphoma, ande others.3,4 Useful clinical agent for the treatment of various blood cancers. Low-dose treatment of T-cell-inflamed tumor models of head and neck cancers with Duvelisib enhanced responses to PD-L1 blockade via suppression of myeloid-derived suppressor cells.5 Higher doses reversed the effect due to suppression of tumor-infiltrating T lymphocytes

Related Content: